BSE filing, NSE: ENTERO. Summary written from the filing by ALFA Finder's alert engine.
Entero Healthcare Solutions Ltd: key numbers
- Share price
- ₹1,585.00
- Market cap
- ₹6,905 Cr
- Revenue (annual)
- ₹6,591 Cr
- Net profit (annual)
- ₹115.0 Cr
- P/E (TTM)
- 55.1×Sector 51.1×
- Promoter holding
- 52.40%+0.00% QoQ
- FII holding
- 5.76%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Entero Healthcare Solutions Ltd
All →Entero Healthcare Solutions Board Meeting Date
Entero Healthcare Solutions scheduled a board meeting for November 04, 2026, to consider and approve unaudited financial results for the quarter ended September 30, 2026.
Entero Healthcare Solutions Other Announcement
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ending September 2026.
Entero Healthcare Solutions Employee Stock Options
Entero Healthcare allotted 43,155 equity shares to employees upon exercise of stock options. The total consideration amounts to ₹4.24 Crore.
- Value
- ₹4.24 Cr
Entero Healthcare Solutions Capital Structure Change
Surbhi Singh (Prasid Uno Family Trust), a non-promoter, sold 21.30 lakh Entero Healthcare shares via bulk/block deals. Stake fell from 7.94% to 3.05%; no transaction value disclosed.
Entero Healthcare Solutions Legal & Regulatory
Entero Healthcare Solutions reported a GST penalty of Rs. 0.13 Crore imposed on its subsidiary, ACE Cardiopathy Solutions, for non-generation of an E-Invoice.
- Value
- ₹0.13 Cr
Entero Healthcare Solutions Capital Structure Change
Prasid Uno Family Trust acquired 10,88,500 shares (2.50%) of Entero Healthcare Solutions Ltd via a block deal. Post-transaction, their total stake is 6.93%.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.